Trial Profile

Efficacy, Safety, and Steroid Sparing Effect of Acthar in Patients With Hematologic Manifestations of Systemic Lupus Erythematosus

Status: Withdrawn prior to enrolment

Phase of Trial: Phase IV

Latest Information Update: 20 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Corticotropin (Primary)
Indications Systemic lupus erythematosus
Focus Therapeutic Use

Most Recent Events

14 May 2025 According to Mallinckrodt plc media release, the data from this study will be presents as a poster at the International Congress on Systemic Lupus Erythematosus (LUPUS 2025), taking place in Toronto, Canada from May 21-24, 2025.
11 Sep 2019 Planned End Date changed from 1 Mar 2019 to 22 May 2019.
11 Sep 2019 Planned primary completion date changed from 1 Mar 2019 to 22 May 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com